KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway

Yitong Xu¹, Chenglong Wang², Xizi Jiang³, Yao Zhang³, Hongbo Su¹, Jun Jiang⁴, Hongjiu Ren³ and Xueshan Qiu¹,³

Abstract

Lung cancer is the leading cause of cancer-related death worldwide. KLHL38 has been reported to be upregulated during diapause but downregulated after androgen treatment during the reversal of androgen-dependent skeletal muscle atrophy. This study aimed to clarify the role of KLHL38 in non-small cell lung cancer (NSCLC). KLHL38 expression was evaluated in tumor and adjacent normal tissues from 241 patients with NSCLC using immunohistochemistry and real-time PCR, and its association with clinicopathological parameters was analyzed. KLHL38 levels positively correlated with tumor size, lymph node metastasis, and pathological tumor-node-metastasis stage (all \( P < 0.001 \)). In NSCLC cell lines, KLHL38 overexpression promoted PTEN ubiquitination, thereby activating Akt signaling. It also promoted cell proliferation, migration, and invasion by upregulating the expression of genes encoding cyclin D1, cyclin B, c-myc, RhoA, and MMP9, while downregulating the expression of p21 and E-cadherin. In vivo experiments in nude mice further confirmed that KLHL38 promotes NSCLC progression through Akt signaling pathway activation. Together, these results indicate that KLHL38 is a valuable candidate prognostic biomarker and potential therapeutic target for NSCLC.

Introduction

Lung cancer is a major global public health concern. Lung cancer accounts for 11.4% of all new cancer cases diagnosed worldwide and is the second most common cancer overall¹. Lung cancer remains the leading cause of cancer-related death, 1.8 million people die annually due to this malignancy. Approximately 85–90% of lung cancer cases are diagnosed as non-small cell lung cancer (NSCLC)². The 5-year survival rates for NSCLC vary within 4–17%, depending on the stage and region. Whenever possible, surgery is the best treatment strategy for NSCLC; however, patients may have a local or systemic recurrence and ultimately succumb to the disease. The prognosis of patients with NSCLC mainly correlates with tumor metastasis, which is associated with the transcriptional regulation of critical genes³–⁴, therefore, it is necessary to identify pro-metastatic genes and investigate their effects in detail.

The PI3K/Akt signaling pathway is commonly dysregulated in various cancers, including lung cancer³, and plays a key role in cancer development. Phosphorylated (p)-Akt, the activated form of Akt, is highly expressed in several human cancers and is associated with survival rate in some cancer types. Akt is commonly phosphorylated at two sites, Ser473 and Thr308, which result in full or partial activation, respectively. PI3K-related kinase family members, including DNA-PK, can phosphorylate Akt at Ser473. In contrast, Akt can be dephosphorylated by protein phosphatase 2A and PH domain leucine-rich repeat inclusion protein phosphatase. The tumor suppressor phosphatase and tensin homologous protein (PTEN) is also a major negative regulator of Akt via PIP3 dephosphorylation⁵–⁸.
PTEN is a powerful tumor suppressor, even a partial reduction in its expression leads to increased cancer susceptibility. Several studies have reported a consistently low PTEN mutation rate (~2–7%) in lung cancer. In contrast, the rate of PTEN loss is reported to be high in lung cancer. PTEN-negative lung cancer patients with lymph node metastasis, who are usually smokers, have the worst survival rates. The development of tyrosine kinase inhibitors targeting epidermal growth factor receptor (EGFR), such as gefitinib, afatinib, and erlotinib, has been a breakthrough for treating patients with NSCLC who carry EGFR mutations. However, the emergence of resistance to EGFR tyrosine kinase inhibitors is almost inevitable in these oncogene-affected tumors, among which PTEN deletion and low PTEN levels are strong and independent predictors of poor outcomes. The most critical function of PTEN is to negatively regulate the PI3K/Akt pathway, thereby inhibiting uncontrolled cell proliferation, growth, and migration. However, the lack of genetic alterations, such as mutations and deletions, in PTEN in lung cancer does not correlate with the observed loss of protein, suggesting a possible role for post-transcriptional regulation.

KLHL38 is a member of the KLHL family and contains a BTB domain, a back domain, and six kelch domains. KLHL38 expression is reportedly upregulated during diapause and downregulated after androgen treatment during the reversal of androgen-dependent skeletal muscle atrophy, in which the Akt signaling pathway is involved. Using database mining and analysis, KLHL38 may be a potential indicator for prognosis of lung adenocarcinoma and squamous cell carcinoma. Moreover, database searches have also suggested that KLHL38 could be involved in NSCLC via the Akt signaling pathway.

According to the Kaplan–Meier database, KLHL38 may act as a tumor promoter in NSCLC. However, the role of KLHL38 in lung cancer is currently unclear. No data are available regarding the expression pattern and clinical significance of KLHL38 in NSCLC. Thus, this study aimed to determine the role of KLHL38 in human NSCLC cells.

Materials and methods

Patients and specimens

A total of 241 tissue specimens from patients with NSCLC, surgically treated between 2013 and 2017, were randomly selected from the Pathology Archive of the First Affiliated Hospital of China Medical University. Among the 241 samples, 43 and 16 samples of NSCLC tumor and paracancerous lung tissue from surgical procedures in 2015, respectively, were randomly selected for real-time PCR and western blot analysis. None of the 241 patients who participated in the pathological correlation analysis received preoperative chemotherapy or radiotherapy. Clinicopathological information was obtained from the clinical records of the patients. This study was approved by the Medical Research Ethics Committee of China Medical University, and informed consent was obtained from all patients.

Immunohistochemistry

The instruments and methods used for immunohistochemical analyses were described previously. Immuno-staining with an anti-KLHL38 rabbit polyclonal antibody (1:100; Sigma-Aldrich, St. Louis, MO, USA) was performed at 4 °C for 18 h. The signal was visualized using Elivision Super HRP (Mouse/Rabbit) IHC Kits (Maixin-Bio, Fuzhou, China) and 3,3’-diaminobenzidine (Maixin-Bio); nuclei were counterstained with hematoxylin. The sections were dehydrated in ethanol before mounting.

Single-blinded scoring of the KLHL38 staining intensity was performed as follows: 0 (no staining), 1 (weak staining), 2 (moderate staining), and 3 (high staining). Scores for the percentage of cells stained were assigned as 0 (0%), 1 (1–30%), 2 (31–70%), and 3 (71–100%). The two scores for each tumor sample were multiplied to obtain a final score ranging from 0 to 9, with scores ≥ 3 being considered KLHL38-positive and scores <3 being considered KLHL38-negative.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from 43 pairs of fresh clinical lung tumor tissues with matched adjacent normal lung tissues using TRIzol reagent (ThermoFisher Scientific, Waltham, MA, USA). RNA in the aqueous phase was precipitated using trichloromethane, isopropanol, and 70% ethanol. Reverse transcription was performed using PrimeScriptRT Reagent Kits with gDNA Eraser (Takara Bio, Beijin, China). qRT-PCR was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using SYBR Green PCR Master Mix (Takara Bio) in 20 μl final volume with the following thermocycling conditions: 95˚C for 30 s, followed by 45 cycles at 95˚C for 5 s, then 60˚C for 30 s. A melting curve was generated to confirm the specificity of amplification. Relative gene expression was calculated using the 2^-ΔΔCt method with ACTB as the internal control. The primer sequences used were as follows: KLHL38 (forward) 5’-GGCCCTCATGTTGAGTCG-3’ and (reverse) 5’-ATCGTTGCGATGAAGTGG-3’; ACTB (forward) 5’-ATAGCACACCGCTGGATAGCAACGTAC-3’ and (reverse) 5’-CACCTTCTACAATGAGCTGTAC-3’; PTEN (forward) 5’-CCCAGTTGTTGCTG GCCAGC-3’ and (reverse) 5’-ATGAGCTTGTCCTCAGCGCCG-3’.
the validity of amplification. All experiments were performed in triplicate.

Cell culture and treatment

The lung cancer cell lines A549, H1299, H460, H661, and SK-MES-1 were purchased from the Cell Bank of the China Academy of Sciences (Shanghai, China), and normal bronchial epithelial HBE cells were obtained from the American Type Culture Collection (Manassas, VA, USA). A549, H1299, H460, and H661 cells were cultured in RPMI 1640 medium (Gibco, Waltham, MA, USA), SK-MES-1 cells were cultured in minimal essential medium (Gibco) containing 1.5 g/l NaHCO₃ and 0.11 g/l sodium pyruvate, and HBE cells were cultured in Dulbecco’s modified Eagle medium (Gibco) containing 1.5 g/l NaHCO₃. All media were supplemented with 10% fetal bovine serum (CLARK Bioscience, Richmond, VA, USA). The cells were maintained in a 5% CO₂ humidified incubator at 37 °C.

Cells were transfected using Lipofectamine 3000 (Invitrogen, Waltham, MA, USA) according to the manufacturer’s instructions. For KLHL38 knockdown experiments, cells were transfected with KLHL38-specific siRNA or scrambled control siRNA (GenePharma, Shanghai, China) for 48 h. For KLHL38 overexpression, cells were transfected with a pCMV6-myc-DDK-KLHL38 plasmid or the corresponding pCMV6-myc-DDKempty vector.

To inhibit PTEN signaling, cells were treated with the PTEN inhibitor HY-128693 (10 µM, SelleckChem, Houston, TX, USA) in DMSO (Sigma-Aldrich). Cells were treated with HY-128693 or an equal volume of DMSO 6 h after transfection and incubated for 36 h.

Immunocytochemistry

Lung cancer cell lines were cultured in 24-well plates for 24 h, fixed using 2% paraformaldehyde for 15 min, blocked with 5% bovine serum albumin for 2 h, and incubated with an anti-KLHL38 antibody (1:100) for 18 h, followed by the addition of a fluorescein isothiocyanate-conjugated secondary antibody (Beyotime Biosciences, Shanghai, China) for 2 h; nuclei were counterstained with DAPI (Beyotime) for 15 min. Cell images were captured using an Olympus FV3000 laser-scanning confocal microscope (Olympus, Tokyo, Japan). The exposure time varied with the intensity of the fluorescent signal.

Western blotting

The expression of proteins directly influencing cell migration and invasion and those involved in cell proliferation and cell cycle progression was analyzed using western blotting. Total protein from cells and tumor tissues was extracted with lysis buffer and quantified using the Bradford method. Proteins (80 µg/lane) were separated using 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), transferred onto polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA), and incubated overnight at 4 °C with the appropriate primary antibodies (Table 1), followed by addition of a horseradish peroxidase-conjugated anti-mouse/rabbit

Table 1 List of antibodies used for western blotting.

| Target  | Source                  | Catalog number | Host       | Dilution |
|---------|-------------------------|----------------|------------|----------|
| KLHL38  | Sigma-Aldrich           | HPA030464      | Rabbit     | 1:500    |
| GAPDH   | Beyotime                | AF0006         | Mouse      | 1:1000   |
| β-Actin | Beyotime                | AA128          | Mouse      | 1:1000   |
| RhoA    | Cell Signaling Technology | 2117         | Rabbit     | 1:500    |
| MMP9    | Cell Signaling Technology | 13667        | Rabbit     | 1:500    |
| Cyclin D1 | Cell Signaling Technology | 2978        | Rabbit     | 1:500    |
| CyclinB1 | Cell Signaling Technology | 12231       | Rabbit     | 1:500    |
| p21     | Cell Signaling Technology | 2947         | Rabbit     | 1:1000   |
| c-Myc   | Cell Signaling Technology | 13987        | Rabbit     | 1:500    |
| E-Cadherin | Cell Signaling Technology | 3195       | Rabbit     | 1:500    |
| PTEN    | Cell Signaling Technology | 9188         | Rabbit     | 1:500    |
| Akt     | Cell Signaling Technology | 9272         | Rabbit     | 1:500    |
| P-Akt (Ser473) | Cell Signaling Technology | 4060      | Rabbit     | 1:500    |
| Anti-mouse IgG | Cell Signaling Technology | 7076     | Horse      | 1:1000   |
| Anti-rabbit IgG | Cell Signaling Technology | 7074     | Goat       | 1:1000   |
IgG secondary antibody at 37 °C for 2 h. Immune reactivity was detected using enhanced chemiluminescence (ThermoFisher Scientific) on a BiolImaging System (UVP Inc., Upland, CA, USA). Relative protein levels were calculated after normalization to GAPDH, which was used as a loading control.

**Gelatin zymograph assay**

Cells were seeded onto 6-well plates and incubated in a serum-free medium for 24 h. Supernatants were then collected and the protein concentration was quantified. The cell supernatants were mixed with 4× SDS loading buffer followed by electrophoresis on 10% SDS-PAGE gels containing 1% gelatin at 4 °C. The gel was washed with eluent buffer (2.5% Triton X-100, 50 mmol/l Tris-HCl, 5 mmol/l CaCl₂, pH 7.6) for 15 min four times, and rinsed (50 mmol/l Tris-HCl, 5 mmol/l CaCl₂, pH 7.6) for 20 min twice. The gels were then incubated in reaction buffer (50 mmol/l Tris-HCl, 5 mmol/l CaCl₂, 0.02% Brij-35, pH 7.6) at 37 °C for 48 h, stained with 0.05% Coomassie brilliant blue for 3 h, and destained with buffer containing 30% methanol and 10% acetic acid for 2 h before each band was photographed.

**Co-immunoprecipitation assays**

Cells were plated in 10-cm dishes. Cell monolayers were lysed using NP40 and lysates were centrifuged at 4000×g for 20 min. Then, 60 µl of Protein A/G Sepharose (P2012; Beyotime Biosciences) was added to the lysate, blocked for 2 h, then centrifuged at 2000 rpm to remove the magnetic beads. The remaining protein lysate was divided into two parts, and 5 µg target antibody and anti-mouse/rabbit IgG beads. The remaining protein lysate was divided into two parts, and 5 µg target antibody and anti-mouse/rabbit IgG were added to each part and incubated overnight at 4 °C while shaking in a chromatography cabinet. The next day, 25 µl agarose A/G magnetic beads were added to each tube and incubated at 4 °C for 6 h; the cell lysate was then washed with lysis buffer and the tubes were heated in boiling water for 10 min. The samples were then used for western blotting.

**Ubiquitination assays and immunoprecipitation**

The ubiquitination and immunoprecipitation assays were performed as described previously.²³,²⁴

**Cell proliferation and colony formation assays**

Cell proliferation and colony formation assays were performed as described previously.¹⁷

**Cell migration and invasion analysis**

Cell migration and invasion assays using the A549 and H1299 cell lines were performed as described previously.¹⁷ Assays with SK-MES-1 cells were performed using the same experimental protocol, but the number of inoculated cells was 8 × 10⁴ cells/100 µl culture medium.

**Tumor formation in nude mice**

Nude mice used in this study were handled following the experimental animal ethics guidelines issued by the China Medical University.

Four-week-old female BALB/c nude mice were purchased from Slac (Shanghai, China) and were maintained in a laminar-flow cabinet under specific pathogen-free conditions for one week before use. Each mouse was inoculated subcutaneously in the right axilla with 1 × 10⁷ tumor cells (KLHL38-transfected A549 and SK-MES-1 cells, or the corresponding vector-transfected control cells) in 0.2 ml sterile phosphate-buffered saline (PBS) or in the tail vein with 1 × 10⁶ tumor cells in 0.1 ml PBS. Four or 8 weeks after axilla and tail vein inoculation, respectively, the mice were euthanized, and necropsies were performed to examine tumor growth and dissemination. A portion of tissue from the tumor and each organ was fixed in 4% formaldehyde (Sigma-Aldrich) and embedded in paraffin. Serial 4-µm-thick sections were cut and stained with hematoxylin and eosin and examined microscopically. The animal care and experimental protocols were approved by the Medical Research Ethics Committee of the China Medical University (CMU2020406).

**Statistical analysis**

SPSS v16.0 software (SPSS Inc., Chicago, IL, USA) was used for data analysis. Correlations between KLHL38 expression and clinicopathological features were determined using the chi-square test, and differences between cell groups were determined using paired t-tests. Results with two-sided P < 0.05 were considered statistically significant.

**Results**

**KLHL38 is overexpressed in NSCLC and correlates with clinicopathological parameters**

Immunocytochemical analysis indicated that KLHL38 was localized in both the cytoplasm and nuclei of A549, H1299, H460, H661, and SK-MES-1 cells and normal bronchial epithelial HBE cells (Fig. 1A).

Overall, 43 matched pairs of clinical lung cancer and normal tissue samples were selected for RNA extraction, and KLHL38 levels were measured. KLHL38 levels were significantly higher in cancers than in matched normal tissues (single sample paired t-test, P = 0.000) (Fig. 1B).

Western blotting confirmed that KLHL38 levels were higher in 14 of the 16 lung cancer tissues analyzed than in matched normal tissues (Fig. 1C). Moreover, immunohistochemical results showed that KLHL38 was overexpressed in clinical lung cancer tissues, whereas in normal bronchi and alveoli, KLHL38 was minimally expressed. Correlation (cross table) analysis with clinicopathological factors revealed that KLHL38 expression
Fig. 1 Expression of KLHL38 in non-small cell lung cancer (NSCLC) cells is associated with poor clinical prognosis. A Immunofluorescence was performed to detect KLHL38 localization in NSCLC cell lines and human normal bronchial epithelial cells. B Relative expression of KLHL38 in 43 paired NSCLC samples (orange bars) and paracancerous lung tissue (purple bars). C KLHL38 levels in 14 lung cancer tissues and matched normal tissues. D KLHL38 levels in alveolar (i) and normal bronchial epithelial cells (ii), well-differentiated squamous cell carcinoma (iii) and adenocarcinoma (iv), and poorly differentiated squamous cell carcinoma (v) and adenocarcinoma (vi) using immunohistochemistry. Magnification: ×200. E Survival analysis of NSCLC patients with high and low KLHL38 expression in lung adenocarcinoma (i) and lung squamous cell carcinoma (ii) based on TCGA data. F Survival of NSCLC patients with high and low KLHL38 expression analyzed based on the results of the present study.
Table 2  Association of KLHL38 expression with clinical and pathological characteristics of patients.

| Clinicopathological characteristics | NSCLC | P-value | Lung adenocarcinoma | P-value | SCC | P-value |
|-------------------------------------|-------|---------|---------------------|---------|-----|---------|
|                                    | Samples (N) KLHL38-positive | KLHL38-negative | P-value | Samples (N) KLHL38-positive | KLHL38-negative | P-value | Samples (N) KLHL38-positive | KLHL38-negative | P-value |
| Age (years) ≤60                   | 129   | 64      | 65                  | 0.699   | 54  | 26      | 0.856   | 58  | 33      | 0.854 |
|                                     | 112   | 59      | 53                  | 0.000   | 72  | 24      | 0.000   | 70  | 27      | 0.000 |
| Age (years) >60                   | 68    | 31      | 37                  | 0.170   | 43  | 20      | 0.022   | 49  | 39      | 0.000 |
| Gender Male                        | 160   | 86      | 74                  | 0.198   | 60  | 24      | 0.000   | 54  | 16      | 0.000 |
| Gender Female                      | 81    | 37      | 44                  | 0.458   | 60  | 24      | 0.000   | 54  | 16      | 0.000 |
| Differentiation Well-moderate      | 162   | 88      | 74                  | 0.170   | 74  | 37      | 0.000   | 74  | 37      | 0.000 |
| Differentiation Poor               | 79    | 35      | 44                  | 0.000   | 74  | 37      | 0.000   | 74  | 37      | 0.000 |
| Tumor size (cm) ≤3                 | 134   | 47      | 87                  | 0.000   | 42  | 26      | 0.000   | 42  | 26      | 0.000 |
| Tumor size (cm) >3                 | 107   | 31      | 76                  | 0.000   | 42  | 26      | 0.000   | 42  | 26      | 0.000 |
| Lymph node metastasis Negative     | 142   | 51      | 91                  | 0.000   | 50  | 33      | 0.000   | 49  | 39      | 0.000 |
| Lymph node metastasis Positive     | 99    | 72      | 27                  | 0.000   | 50  | 33      | 0.000   | 49  | 39      | 0.000 |
| TNM stage I                        | 102   | 23      | 79                  | 0.000   | 55  | 15      | 0.000   | 47  | 8       | 0.000 |
| TNM stage II–III                   | 139   | 100     | 39                  | 0.000   | 67  | 42      | 0.000   | 72  | 58      | 0.000 |
| Histological type SCC              | 119   | 66      | 53                  | 0.000   | 67  | 42      | 0.000   | 72  | 58      | 0.000 |
| Histological type Adenocarcinoma   | 122   | 57      | 65                  | 0.019   | 67  | 42      | 0.000   | 72  | 58      | 0.000 |

NSCLC non-small cell lung carcinoma, SCC squamous cell carcinoma, TNM Eighth Edition of tumor-node-metastasis classification.
did not correlate with the tumor histological type \( (P = 0.198) \), degree of differentiation \( (P = 0.170) \), patient age \( (P = 0.699) \), or sex \( (P = 0.276) \), but did correlate positively with tumor size \( (P = 0.000) \), lymph node metastasis \( (P = 0.000) \), and p-TNM stage \( (P = 0.000) \). Statistical analyses were performed for all cases, as well as separately for adenocarcinoma and squamous cell carcinoma (Table 2). KLHL38 differential expression results are shown in Fig. 1D. Analysis of The Cancer Genome Atlas (TCGA) database also showed a differential correlation of KLHL38 expression with patient prognoses (Fig. 1E). Of note, statistical analysis of clinical samples suggested that high expression of KLHL38 was associated with poor prognosis (Fig. 1F), whereas statistical analysis of TCGA data for lung adenocarcinoma (Fig. 1E-i) and lung squamous carcinoma (Fig. 1E-ii) suggested the opposite.

**KLHL38 promotes the migration and invasion of lung cancer cells**

As KLHL38 expression was correlated with lymph node metastasis, we speculated that KLHL38 could be related to the migration and invasion of lung cancer cells. To study the role of KLHL38 in NSCLC, its expression was first evaluated in several cancer cell lines (Fig. 2A), of which A549, H1299, and SK-MES-1 cells had low, high, and intermediate levels of KLHL38, respectively; hence, these cell lines were selected for studying the effects of KLHL38 expression. KLHL38 was knocked down using siRNA transfection and upregulated by transfecting with a pCMV6-myc-DDK-KLHL38 plasmid. In both A549 and H1299 adenocarcinoma cells and in SK-MES-1 squamous cells, Moreover, KLHL38 expression was significantly associated with the promotion of migration and invasion (Fig. 2B). Variations in KLHL38 levels also affected the expression of proteins involved in migration and invasion. Overexpression of KLHL38 resulted in upregulation of RhoA and MMP9 and downregulation of E-cadherin. These effects were reversed by KLHL38 knockdown (Fig. 2C). Gelatinase analysis showed that KLHL38 could positively regulate the secretion of active MMP9 (Fig. 2D). Collectively, these findings demonstrate that KLHL38 promotes the migration and invasion of lung cancer cells.

**KLHL38 promotes the proliferation of lung cancer cells**

The effect of KLHL38 expression on tumor size was evaluated as a reflection of cell proliferation. In A549 and SK-MES-1 cells, KLHL38 upregulation promoted clone formation, whereas, in H1299 and SK-MES-1 cells, KLHL38 downregulation had the opposite effect (Fig. 3A). Analysis of proteins involved in cell proliferation indicated that the levels of cyclin D1, cyclin B, and c-myc were upregulated, whereas p21 was downregulated upon KLHL38 overexpression. KLHL38 downregulation had the opposite effects (Fig. 3B).

**KLHL38 promotes NSCLC progression via Akt signaling pathway activation**

As cell proliferation-related proteins are targeted by the Akt signaling pathway, we next investigated if the potential relationship with KLHL38 existed. PTEN/PI3K/AKT constitutes an important pathway regulating the signaling of multiple biological processes such as apoptosis, metabolism, cell proliferation, and cell growth. The Akt inhibitor AKT VIII (MCE, Monmouth Junction, NJ, USA) and si-PTEN were used separately to verify the function of PTEN/PI3K/Akt/phospho-Akt in this pathway. Downregulation of PTEN caused an upregulation of p-AKT (Supplementary Fig. S1A), while treatment with Akt VIII caused decreases in Akt and p-Akt expression, but no effect was observed on PI3K and PTEN expression (Supplementary Fig. S1B). PTEN can therefore inhibit the Akt pathway through inhibition of Akt phosphorylation. PTEN was found to be significantly upregulated in the three analyzed cell lines, whereas p-Akt (Ser473) was downregulated after KLHL38 knockdown; KLHL38 upregulation had the opposite effect (Fig. 3C).

To investigate whether KLHL38 could promote Akt activation by reducing PTEN levels, the PTEN inhibitor HY-128693 was used. In H1299 and SK-MES-1 cells transfected with KLHL38-siRNA, HY-128693 partially reduced the induction of cell migration, invasion, and proliferation (Fig. 4A, B), reversed the effects of KLHL38 knockdown on protein expression (Fig. 4C), and induced secretion of active MMP9 (Fig. 4D). These results suggest that KLHL38 overexpression activates the Akt pathway via PTEN inhibition.

**KLHL38 interacts with PTEN and promotes its ubiquitination and degradation**

Results of co-immunoprecipitation experiments revealed that KLHL38 directly interacts with PTEN in lung cancer cells (Fig. 5A). However, the qRT-PCR analysis indicated that PTEN expression was unchanged regardless of KLHL38 expression in lung cancer cell lines (Fig. 5B), indicating that the interaction between KLHL38 and PTEN may occur at the protein rather than mRNA level. Considering that the members of the KLHL protein family possess ubiquitination ability, KLHL38 could also contribute to the activation of the Akt signaling pathway by enhancing PTEN ubiquitination. Therefore, HA-ubiquitin was transfected into cells, along with siRNA or plasmids, which were then treated with the 26S proteasome inhibitor MG132. Next, PTEN ubiquitination levels were evaluated by immunoprecipitation with an anti-PTEN antibody, followed by anti-HA immunoblotting. The results revealed a positive correlation between KLHL38 expression and PTEN ubiquitination (Fig. 5C), suggesting that KLHL38 activates the Akt pathway by facilitating ubiquitin-dependent degradation of PTEN.
Fig. 2 Effect of KLHL38 expression on the migration and invasion of non-small cell lung cancer (NSCLC) cells. A KLHL38 levels in HBE cells and seven NSCLC cell lines determined by western blotting. B Cell migration evaluated by the transwell migration assay; cells that migrated to the lower chamber were stained with hematoxylin and counted. *P < 0.05; **P < 0.01. C Expression of KLHL38 and cell migration- and invasion-related proteins in A549, H1299, and SK-MES-1 cells. Relative quantification of western blot data was based on densitometry analysis. p-NC, cells transfected with pCMV6-myc-DDK; p-38, cells transfected with pCMV6-myc-DDK-KLHL38; si-NC, cells transfected with scrambled control siRNA; si-38, cells transfected with KLHL38-specific siRNA. D Gelatin zymograph assay showing the relationship between KLHL38 and secreted active MMP9. All experiments were repeated three times, error bars as s.d.
Fig. 3 Effect of KLHL38 expression on colony formation and Akt signaling. A Colony formation assay. A549: pCMV6-myc-DDK-KLHL38 (p-38) vs. pCMV6-myc-DDK (p-NC), \( P = 0.0278 \). H1299: KLHL38-specific siRNA (si-38) vs. scrambled control siRNA (si-NC), \( P = 0.0189 \); SK-MES-1: p-38 vs. p-NC, \( P = 0.0391 \), si-38 vs. si-NC, \( P = 0.0318 \). B Changes in the expression of proliferation-related proteins in A549, H1299, and SK-MES-1 cells. p-NC, cells transfected with pCMV6-myc-DDK; p-38, cells transfected with pCMV6-myc-DDK-KLHL38; si-NC, cells transfected with scrambled control siRNA; si-38, cells transfected with KLHL38-specific siRNA. All experiments were repeated three times, error bars as s.d.
Fig. 4 Effect of KLHL38 expression with or without PTEN inhibition on non-small cell lung cancer (NSCLC) cells. A Migration, invasion, and colony formation assays of H1299 and SK-MES-1 cells transfected with a KLHL38-specific siRNA were reversed upon incubation with the PTEN inhibitor HY-128693, compared to DMSO treated cells. C Expression of proteins involved in cell proliferation, migration, invasion, and the Akt signaling in A549, H1299, and SK-MES-1 cells transfected with a KLHL38-specific siRNA upon treatment with DMSO or the PTEN inhibitor HY-128693. si-NC, cells transfected with scrambled control siRNA; si-38, cells transfected with KLHL38-specific siRNA. D Gelatin zymograph assay showing the changes of secreted active MMP9. All experiments were repeated three times, error bars as s.d.
KLHL38 promotes cell proliferation, migration, and invasion in vivo

A549 and SK-MES-1 cells were used to generate stably transfected cell lines using G418 and the relevant plasmids. Changes in KLHL38 expression in these cells positively affected the xenograft tumor volume (Fig. 6A) and weight (Fig. 6B). The lung metastatic rate (5/5 vs. 1/5 and 4/5 vs. 1/4 for A549 and SK-MES-1, respectively) and the number of lung metastatic nodules in mice transplanted with A549-KLHL38(+) or SK-MES-1-KLHL38 (+) cells were significantly greater than those in the control group (Fig. 6C). These in vivo results further confirm that KLHL38 overexpression enhances the proliferation, migration, and invasion of NSCLC cells.

Discussion

This study demonstrated that KLHL38 localizes in the cytoplasm and nucleus, and that its expression level correlates with a range of clinicopathological parameters in NSCLC, including tumor size, lymph node metastasis, and pathological tumor-node-metastasis stage. We used a 3 cm cut-off value to determine T1 and T2 in the p-TNM stage of lung cancer. Our statistical study found that the cut-off value for KLHL38 and tumor size was exactly the referred value, which also suggests clinical significance. In vitro and in vivo experiments using NSCLC cell lines confirmed that KLHL38 promotes their proliferation, migration, and invasion. In vitro experiments using the adenocarcinoma cell lines A549 and H1299 and the
squamous cell line, SK-MES-1 demonstrated that KLHL38 promotes migration and invasion by upregulating RhoA and MMP9 and downregulating E-cadherin. To promote proliferation, KLHL38 also positively regulates cyclin D1, cyclin B, and c-myc, whereas it negatively regulates p21.

The role of the Akt pathway in cancer is well-established. In the present study, KLHL38 was found...
to promote activation of Akt and its downstream partners by promoting ubiquitin-dependent PTEN degradation. A previous study on KLHL18, another member of the KLHL family, demonstrated that the BTB domains in KLHL18 are critical for the ubiquitination of PI3Kp85α. However, it was not possible here to identify which KLHL38 domains are involved in the PTEN ubiquitination process. Thus, further studies are warranted. PTEN activity is lost by mutation, deletion, or promoter methylation silencing at high frequency in many primary and metastatic human cancers. A549 has a higher number of methylated CpG sites in PTEN. Increased PTEN ubiquitination induced by KLHL38 may also be involved. Moreover, the relationship between KLHL38 and PTEN with respect to the clinical-pathological features of NSCLC remains to be elucidated.

Altogether, these results indicated that KLHL38 promotes the proliferation, migration, and invasion of NSCLC cells, which are correlated with NSCLC clinicopathological parameters. The present data on the survival of NSCLC patients differed from those from the TCGA, possibly because the data were collected from patients with different racial ethnicities. Data from more patients are needed to reduce sampling errors. Collectively, these findings suggest that KLHL38 is a candidate prognostic biomarker and potential therapeutic target for NSCLC.

Acknowledgements
We would like to thank Editage (www.editage.com) for English language editing.

Author details
1Department of Pathology, The First Affiliated Hospital, China Medical University, 110000 Shenyang, China. 2Department of Pain Medicine, The First Affiliated Hospital, China Medical University, 110000 Shenyang, China. 3Department of Pathology, College of Basic Medical Sciences, China Medical University, 110000 Shenyang, China. 4Department of Pathology, The First Afﬁliated Hospital, China Medical University, 110000 Shenyang, China.

Author contributions
Y.X.: conceptualization, methodology, validation, and writing - original draft. C.W.: data curation. X.J.: methodology. Y.Z.: validation. H.S.: resources and validation. J.J.: methodology. H.R.: resources.

Funding
This work was supported by the National Natural Science Foundation of China (Grant No. 81902337 to Y.X.).

Data availability
The results published here are in part based upon data generated by the TCGA Research Network (https://www.cancer.gov/tcga). The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics statement
This study was approved by the Medical Research Ethics Committee of China Medical University [AF-SOP007-1.1-01]. The animal care and experimental protocols were approved by the Medical Research Ethics Committee of the China Medical University (CMU2020406).

Conflict of interest
The authors declare no competing interests.

Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1038/s41419-021-03833-0.

Received: 16 February 2021 Revised: 8 May 2021 Accepted: 10 May 2021

Published online: 28 May 2021

References
1. Sung, H et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. https://doi.org/10.3332/caac.21660 (2021).
2. Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2016. CA Cancer J. Clin. 66, 7–30 (2016).
3. Fred, R. H. et al. Lung cancer: current therapies and new targeted treatments. Lancet 389, 299–311 (2017).
4. Khanna, P., Blais, N., Gaudreau, P. O. & Coronas-Rodriguez, L. Immunotherapy comes of age in lung cancer. Clin. Lung Cancer 18, 13–22 (2017).
5. Gkountakos, A. et al. PTEN in lung cancer: dealing with the problem, building on new knowledge and turning the game around. Cancers 11, 1141 (2019).
6. Camero, A., Blanco-Aparicio, C., Renner, O., Link, W. & Leal, J. F. M. The PTEN/PBKX/ACT signalling pathway in cancer, therapeutic implications. Curr. Cancer Drug Targets 8, 187–198 (2008).
7. Hers, I., Vincent, E. E. & Tavarez, J. M. Akt signalling in health and disease. Cell Signal 23, 1515–1527 (2011).
8. Liu, P., Cheng, H., Roberts, T. M. & Zhao, J. J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627–644 (2009).
9. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
10. Ku, B. M. et al. Molecular screening of small biopsy samples using next-generation sequencing in Korean patients with advanced non-small cell lung cancer: Korean Lung Cancer Consortium (KLCC-13-01). J. Pathol. Transl. Med. 52, 148–156 (2018).
11. Mehrad, M., Roy, S., Bittar, H. T. & Dacic, S. Next-generation sequencing approach to non-small cell lung carcinoma yields more actionable alterations. Arch. Pathol. Lab. Med. 142, 353–357 (2018).
12. Chang, X. J. et al. The clinical significance of loss of FHT and PTEN expression in 289 patients with non-small-cell lung cancer. Transl. Cancer Res. 5, 294–301 (2016).
13. Soo, M. L. et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res. 69, 3256–3261 (2009).
14. Wang, F. et al. Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations. Cancer Commun. 39, 7 (2019).
15. Mesak, F., Tatarinov, A. & Avise, J. C. Transcriptomics of diapause in an isogenic self-fertilizing vertebrate. BMC Genomics 16, 989 (2015).
16. Coelho, P. O. et al. Identification of potential target genes associated with the reversion of androgen-dependent skeletal muscle atrophy. Arch. Biochem. Biophys. 663, 173–182 (2019).
17. Xu, Y. et al. NAAAD2047 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway. Cancer Sci. 109, 1055–1065 (2018).
18. Bravo-Cordero, J. J., Hodgson, L. & Condeelis, J. Directed cell invasion and migration during metastasis. Curr. Opin. Cell Biol. 24, 277–283 (2012).
19. Hanna, S. & El-Sibai, M. Signaling networks of Rho GTPases in cell motility. Cell Signal 25, 1955–1961 (2013).
20. Gong, L. et al. Prognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget 7, 18458–18468 (2017).
21. Hanahan, D. & Weinberg, R. A. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
22. Hall, M. & Peters, G. Genetic alterations of cyclins, cyclin-dependent kinases, and CDK inhibitors in human cancer. Adv. Cancer Res. 68, 67–108 (1996).
23. Jiang, X. et al. KLHL18 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by inhibiting PI3K/PD-L1 axis activity. Cell Biosci. 10, 139 (2020).

24. Jiang, J. et al. MKRN2 inhibits migration and invasion of non-small-cell lung cancer by negatively regulating the PI3K/Akt pathway. J. Exp. Clin. Cancer Res. 37, 189 (2018).

25. Liu, L., Wang, Y. & Yu, Q. The PI3K/Akt signaling pathway exerts effects on the implantation of mouse embryos by regulating the expression of RhoA. Int J. Mol. Med. 33, 1089–1096 (2014).

26. Li, Y., Zhang, C., Cai, D., Chen, C. & Mu, D. Silibinin inhibits migration and invasion of the rhabdoid tumor G401 cell line via inactivation of the PI3K/Akt signaling pathway. Oncol. Lett. 14, 8035–8041 (2017).

27. Zhou, Y. et al. Suppression of STIM1 inhibits the migration and invasion of human prostate cancer cells and is associated with PI3K/Akt signaling inactivation. Oncol. Rep. 38, 2629–2636 (2017).

28. Jung, I. L., Kang, H. J., Kim, K. C. & Kim, I. G. PTEN/pAkt/p53 signaling pathway correlates with the radioresponse of non-small cell lung cancer. Int J. Mol. Med. 25, 517–523 (2010).